Pittsburgh plasma p-tau217: classification accuracies for autosomal dominant and sporadic Alzheimer’s disease in the community
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
INTRODUCTION
Most available p-tau217 immunoassays have similar performances. It is unclear if this is due to the use of the same antibody (the “ALZpath antibody”). We established and evaluated a novel p-tau217 assay that employs an alternative antibody, and benchmarked the results against ALZpath-p-tau217.
METHODS
Following development and analytical validation of the University of Pittsburgh (“Pitt-p-tau217”) method, clinical verification was performed in three independent cohorts (n=363).
RESULTS
Pitt-p-tau217 demonstrated high between-run stability, linearity, and specificity. Clinically, Pitt-p-tau217 differentiated neuropathologically confirmed PSEN1 mutation carriers from controls with AUC=0.94, and Aβ-PET-positive from Aβ-PET-negative cognitively normal older adults with AUC up to 0.84, equivalent to ALZpath-p-tau217 results. Both Pitt-p-tau217 and ALZpath-p-tau217 were elevated in tau-PET-positive versus tau-PET-negative participants (P=0.06; AUC=0.71 for both). Between-assay correlations were up to 0.93.
DISCUSSION
The new Pitt-p-tau217 assay exhibits high and reproducible classification accuracies for identifying individuals with biological evidence of AD, equivalent to the widely used ALZpath-p-tau217.
